Karo Pharma AB (publ) (KARBF) Comparison with companies in other sectors?

Karo Pharma AB (publ) has a share price of 289.68M. You can analyze Karo Pharma AB (publ) (KARBF) competitors across different market sectors through stock heatmaps.

What are KARBF's NET and operating margins?

Karo Pharma AB (publ) (KARBF) operating margin is around N/A, and net profit margin is approximately N/A as of the latest reports.

In what way does KARBF's earnings per share (EPS) trend reflect its financial momentum?

Karo Pharma AB (publ) (KARBF) EPS is 0.02 (If EPS value is positive, then "signals consistent profit growth" if Negative then "signals consistent loss"). This metric is also critical in assessing valuation metrics like the P/E ratio for Karo Pharma AB (publ) is 262.50, and the company's ability to reinvest or distribute profits.

What does a high ROE mean for Karo Pharma AB (publ)?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Karo Pharma AB (publ) like P/E which is N/A, P/B which is N/A, and PEG which is N/A. Compare them with sector averages to evaluate if the stock is priced fairly.

Karo Pharma AB (publ)

KARBF•PNK

Healthcare

Drug Manufacturers - Specialty & Generic

$5.25

$0.00(0.00%)

U.S. Market opens in NaNh NaNm

Karo Pharma AB (publ) Fundamental Analysis

Karo Pharma AB (publ) (KARBF) shows weak financial fundamentals with a PE ratio of 262.50, profit margin of N/A, and ROE of N/A. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

No significant strengths identified.

Areas of Concern

No major concerns flagged.

We analyze KARBF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 0.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

0.0/100

We analyze KARBF's fundamental strength across five key dimensions:

Efficiency Score

Weak

KARBF struggles to generate sufficient returns from assets.

ROA > 10%

N/A

Valuation Score

Weak

KARBF trades at a premium to fair value.

PE < 25

262.50

PEG Ratio < 2

N/A

Growth Score

Moderate

KARBF shows steady but slowing expansion.

Revenue Growth > 5%

N/A

EPS Growth > 10%

N/A

Financial Health Score

Weak

KARBF carries high financial risk with limited liquidity.

Debt/Equity < 1

N/A

Current Ratio > 1

N/A

Profitability Score

Weak

KARBF struggles to sustain strong margins.

ROE > 15%

N/A

Net Margin ≥ 15%

N/A

Positive Free Cash Flow

N/A

Key Financial Metrics

Is KARBF Expensive or Cheap?

P/E Ratio

KARBF trades at 262.50 times earnings. This suggests a premium valuation.

262.50

How Well Does KARBF Make Money?

No data available.

Following the Money - Real Cash Generation

No data available.

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

N/A

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

N/A

vs 25 benchmark

P/B Ratio

Price to book value ratio

N/A

vs 25 benchmark

P/S Ratio

Price to sales ratio

N/A

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

N/A

vs 25 benchmark

Current Ratio

Current assets to current liabilities

N/A

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

N/A

vs 25 benchmark

ROA

Return on assets percentage

N/A

vs 25 benchmark

ROCE

Return on capital employed

N/A

vs 25 benchmark

How KARBF Stacks Against Its Sector Peers

Metric	KARBF Value	Sector Average	Performance
P/E Ratio	N/A	29.78	N/A
ROE	N/A	792.00%	N/A
Net Margin	N/A	-23280.00% (disorted)	N/A
Debt/Equity	N/A	0.25	N/A
Current Ratio	N/A	4.60	N/A
ROA	N/A	-18077.00% (disorted)	N/A

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Karo Pharma AB (publ)'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Karo Pharma AB (publ) Fundamental Analysis

Key Strengths

Areas of Concern

Fundamental Health Score

Efficiency Score

Valuation Score

Growth Score

Financial Health Score

Profitability Score

Key Financial Metrics

Is KARBF Expensive or Cheap?

How Well Does KARBF Make Money?

Following the Money - Real Cash Generation

Financial Ratios Analysis

Valuation Ratios

Financial Health

Efficiency Ratios

How KARBF Stacks Against Its Sector Peers

Historical Growth Performance

5-Year Growth Trajectory

Fundamental Analysis FAQ

Karo Pharma AB (publ) (KARBF) Comparison with companies in other sectors?

What are KARBF's NET and operating margins?

In what way does KARBF's earnings per share (EPS) trend reflect its financial momentum?

What does a high ROE mean for Karo Pharma AB (publ)?

How do I know if AAPL is overvalued or undervalued?